1. Home
  2. BON vs BLRX Comparison

BON vs BLRX Comparison

Compare BON & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bon Natural Life Limited

BON

Bon Natural Life Limited

HOLD

Current Price

$1.30

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.65

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BON
BLRX
Founded
2006
2003
Country
China
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
12.6M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
BON
BLRX
Price
$1.30
$2.65
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
12.6K
23.6K
Earning Date
01-23-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$390.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.13
$2.15
52 Week High
$3.39
$7.77

Technical Indicators

Market Signals
Indicator
BON
BLRX
Relative Strength Index (RSI) 53.24 47.15
Support Level $1.25 $2.66
Resistance Level $1.35 $2.76
Average True Range (ATR) 0.05 0.22
MACD 0.01 -0.03
Stochastic Oscillator 95.94 20.43

Price Performance

Historical Comparison
BON
BLRX

About BON Bon Natural Life Limited

Bon Natural Life Ltd focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by its customers. It has developed four technology platforms for large-scale separation, safety improvement, activity enhancement, and functional compounding of natural products. The company's offerings include Fragrance compounds, Health supplements, and Bioactive food ingredients. The company generates revenue from the sale of its products, the majority derived from the sale of Fragrance compounds, which include natural compounds extracted from plants for cosmetic applications.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: